SCHEMBL1069038

SCHEMBL1069038

CCOC(=O)/C=C(/C)Oc1cccc(OC)c1OC

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 2/20 0.46
LMNA P02545 4/20 0.42
MAPT P10636 3/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
PTPN1 P18031 1/20 0.42
PLIN1 O60240 1/20 0.42
POLB P06746 1/20 0.42
PLIN5 Q00G26 1/20 0.42
ABHD5 Q8WTS1 1/20 0.42
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 3/20 0.41
HPGD P15428 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
MAOB P27338 1/20 0.39
TSHR P16473 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1069034 1.00 NFE2L2 (0.46) NFE2L2LMNAMAPTSMN1; SMN2MEN1
SCHEMBL1069039 1.00 NFE2L2 (0.46) NFE2L2LMNAMAPTSMN1; SMN2MEN1
SCHEMBL1063649 0.87 MAPT (0.48) LMNAMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL1063648 0.87 MAPT (0.48) LMNAMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL1066872 0.85 MAPT (0.41) LMNAMAPTMEN1KMT2APLIN1
SCHEMBL1067483 0.85 MAPT (0.41) LMNAMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL1066869 0.85 MAPT (0.41) LMNAMAPTMEN1KMT2APLIN1
SCHEMBL1067484 0.85 MAPT (0.41) LMNAMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL1067485 0.85 MAPT (0.41) LMNAMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL1067636 0.83 NFE2L2 (0.43) NFE2L2LMNAMAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 NFE2L2 852/4885LMNA 3936/4885MAPT 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.